Automatic Website Traffic RSS

First Patient Treated With Jakafi in Phase 2 Graft-Versus-Host Disease Study

The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is ... read more